As has been pointed out, the fact that a portion of patients have been on drug for longer than 3 years and no safety concerns have been cited by the DSMB will speak well for Apabetalone if the trial is successful.

To me it is always a bit of a numbers crap shoot regarding patients in either test or placebo arms who have an event close to their initial enrolment in a trial. They are at highest risk due to a recent occurrence that qualifies them for trial participation and one wonders if those in the test arm have really been on drug long enough for the drug to have an opportunity for effect. Obviously I hope that top line data shows a large and significant RRR. What I hope even more is that the study will show that test arm patients show an increasing RRR with time on drug as compared to their same time in study placebo counterparts. To me this is the true test as to the effect of a chronic care drug. JMO